Remsima 120 mg solution for injection in pre-filled syringe
Authorisation EU/1/13/853/006-011 · Celltrion Healthcare Hungary Kft.
- Licence holder
- Celltrion Healthcare Hungary Kft. (all products →)
- Active substance
- Infliximab
- Clinical trials
- 29 clinical trials →
- Dosage form
- Solution for injection in pre-filled syringe
- Route of administration
- Subcutaneous use
- ATC code
- L04AB02
- First authorised
- 22/11/2019
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Similar biological application (Article 10(4) of Directive No 2001/83/EC)
Infliximab: supply and approvals
7 authorised products on the HPRA list contain Infliximab. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 853. It has been authorised for 6 years (since 22 November 2019). The HPRA list does not say whether it is on sale.
Other medicines with Infliximab in Ireland
6 other products on the HPRA list contain Infliximab, from 4 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Flixabi 100 mg powder for concentrate for solution for infusion | Samsung Bioepis NL B.V. | Centralised EU authorisation | Not stated |
| Remicade 100 mg Powder for concentrate for solution for infusion | Janssen-Cilag International NV | Centralised EU authorisation | Not stated |
| Remsima 100 mg powder for concentrate for solution for infusion | Celltrion Healthcare Hungary Kft. | Centralised EU authorisation | Not stated |
| Remsima 120 mg solution for injection in pre-filled pen | Celltrion Healthcare Hungary Kft. | Centralised EU authorisation | Not stated |
| Remsima 40 mg/mL concentrate for solution for infusion | Celltrion Healthcare Hungary Kft. | Centralised EU authorisation | Not stated |
| Zessly 100 mg powder for concentrate for solution for infusion | Sandoz GmbH | Centralised EU authorisation | Not stated |
The licence holder
Celltrion Healthcare Hungary Kft. holds 30 products on the HPRA list, with 10 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.